Reich S H, Melnick M, Pino M J, Fuhry M A, Trippe A J, Appelt K, Davies J F, Wu B W, Musick L
Agouron Pharmaceuticals, Inc, San Diego, California 92121, USA.
J Med Chem. 1996 Jul 5;39(14):2781-94. doi: 10.1021/jm960093o.
The design, synthesis, and crystallographic analysis of protein-inhibitor complexes is described for a novel series of nonpeptidic HIV protease (HIV Pr)inhibitors. Beginning with a cocrystal structure of a Phe-Pro peptidomimetic bound to the HIV Pr, design was initiated that resulted in the substituted 2-butanol compound 8 as the lead compound (Ki = 24.5 microM, racemic mixture). Modifications on the initial compound were then made on the basis of its cocrystal structure with HIV Pr and inhibition data, resulting in compounds with enhanced potency against the enzyme (compound 18, Ki = 0.48 microM). These inhibitors were found to bind to the enzyme essentially as predicted on the basis of the original design hypothesis. Stereospecific synthesis of individual enantiomers confirmed the prediction of a binding preference for the S alcohol stereochemistry. Modest antiviral activity was demonstrated for several of the more potent HIV Pr inhibitors in a HIV-1 infected CEM-SS cell line.
本文描述了一系列新型非肽类HIV蛋白酶(HIV Pr)抑制剂的蛋白质-抑制剂复合物的设计、合成及晶体学分析。从与HIV Pr结合的苯丙氨酸-脯氨酸拟肽的共晶体结构出发,开始设计,得到了取代的2-丁醇化合物8作为先导化合物(Ki = 24.5 microM,外消旋混合物)。然后根据其与HIV Pr的共晶体结构和抑制数据对初始化合物进行修饰,得到了对该酶活性增强的化合物(化合物18,Ki = 0.48 microM)。发现这些抑制剂与酶的结合基本上如基于原始设计假设所预测的那样。单个对映体的立体定向合成证实了对S醇立体化学结合偏好的预测。在HIV-1感染的CEM-SS细胞系中,几种更强效的HIV Pr抑制剂表现出适度的抗病毒活性。